ClinicalTrials.gov
public full text
Public Domain
Varenicline Effects In Schizophrenic Smokers
This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder#805707
- Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors#1093608
- Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt#1030434
- Efficacy of Varenicline in Ambivalent Smokers#888164
- Varenicline In-Patient Study#1086693
Record · ID 895660
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive